unknown
Stage
About
Eikonoklastes is a biopharmaceutical company developing first-in-class gene therapies to treat neurodegenerative diseases, with initial focus on ALS using a gene therapy that overexpresses Caveolin-1 to provide neuroprotection.
Explore Eikonoklastes's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.